The 2015 CUA-CUOG Guidelines for the Management of Castration-resistant Prostate Cancer (CRPC)

Overview

Journal Can Urol Assoc J

Specialty Urology

Date 2015 Jun 19

PMID 26085865

Citations 40

Authors

Fred Saad

Kim N Chi

Antonio Finelli

Sebastien J Hotte

Jonathan Izawa

Anil Kapoor

Wassim Kassouf

Andrew Loblaw

Scott North

Ricardo Rendon

Alan So

Nawaid Usmani

Eric Vigneault

Neil E Fleshner

Affiliations

Soon will be listed here.

Abstract

Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance of optimizing the use of these agents, a multidisciplinary team approach is highly recommended.

Citing Articles

Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Gotto G, Yip S, Shayegan B, OSullivan D, Wallis C, Basappa N Can Urol Assoc J. 2024; 19(1):E25-E35.

PMID: 39470659 PMC: 11790044. DOI: 10.5489/cuaj.8691.

Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE).

Ko J, Mbuagbaw L, Tyldesley S, Lowther J, Sunderland K, Royer C Can Urol Assoc J. 2024; 18(7):E194-E203.

PMID: 39074987 PMC: 11286190. DOI: 10.5489/cuaj8620.

AKT, a Key Transmitter of HIF-1α and AR Signaling Pathways, Has a Critical Role in the Apigetrin-Mediated Anti-Cancer Effects in Prostate Cancer Cells.

Lee Y, Kim J, Xu Y, Han H, Lee J, Lee H Biomedicines. 2022; 10(6).

PMID: 35740392 PMC: 9220772. DOI: 10.3390/biomedicines10061370.

Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).

Maluf F, Pereira F, Silva A, Dettino A, Cardoso A, Sasse A JCO Glob Oncol. 2021; 7:559-571.

PMID: 33856891 PMC: 8162971. DOI: 10.1200/GO.20.00511.

Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.

Katano A, Yamashita H, Nakagawa K Cureus. 2021; 13(2):e13199.

PMID: 33717741 PMC: 7943180. DOI: 10.7759/cureus.13199.

References

Oosterhof G, Roberts J, de Reijke T, Engelholm S, Horenblas S, von der Maase H . Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol. 2003; 44(5):519-26. DOI: 10.1016/s0302-2838(03)00364-6. View

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

Porter A, McEwan A . Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol. 1993; 20(3 Suppl 2):38-43. View

Heng D, Chi K . Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. Can J Urol. 2006; 13(6):3335-9. View

Diamond T, Higano C, Smith M, Guise T, Singer F . Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004; 100(5):892-9. DOI: 10.1002/cncr.20056. View

Scher H, Fizazi K, Saad F, Taplin M, Sternberg C, Miller K . Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13):1187-97. DOI: 10.1056/NEJMoa1207506. View

Scher H, Halabi S, Tannock I, Morris M, Sternberg C, Carducci M . Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26(7):1148-59. PMC: 4010133. DOI: 10.1200/JCO.2007.12.4487. View

Michels J, Montemurro T, Murray N, Kollmannsberger C, Chi K . First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?. Cancer. 2006; 106(5):1041-6. DOI: 10.1002/cncr.21695. View

Tran C, Ouk S, Clegg N, Chen Y, Watson P, Arora V . Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324(5928):787-90. PMC: 2981508. DOI: 10.1126/science.1168175. View

10.

Petrylak D, Tangen C, Hussain M, Lara Jr P, Jones J, Taplin M . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351(15):1513-20. DOI: 10.1056/NEJMoa041318. View

11.

de Bono J, Oudard S, Ozguroglu M, Hansen S, Machiels J, Kocak I . Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747):1147-54. DOI: 10.1016/S0140-6736(10)61389-X. View

12.

Smith M, Saad F, Coleman R, Shore N, Fizazi K, Tombal B . Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2011; 379(9810):39-46. PMC: 3671878. DOI: 10.1016/S0140-6736(11)61226-9. View

13.

Saad F . Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int. 2009; 103(4):434-40. DOI: 10.1111/j.1464-410X.2008.08249.x. View

14.

Kantoff P, Schuetz T, Blumenstein B, Glode L, Bilhartz D, Wyand M . Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010; 28(7):1099-105. PMC: 2834462. DOI: 10.1200/JCO.2009.25.0597. View

15.

Smith M, McGovern F, Zietman A, Fallon M, Hayden D, Schoenfeld D . Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001; 345(13):948-55. DOI: 10.1056/NEJMoa010845. View

16.

Smith M, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169(6):2008-12. DOI: 10.1097/01.ju.0000063820.94994.95. View

17.

Mohler J, Gregory C, Ford 3rd O, Kim D, Weaver C, Petrusz P . The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004; 10(2):440-8. DOI: 10.1158/1078-0432.ccr-1146-03. View

18.

Rathkopf D, Smith M, de Bono J, Logothetis C, Shore N, de Souza P . Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014; 66(5):815-25. PMC: 4418928. DOI: 10.1016/j.eururo.2014.02.056. View

19.

Oh W, Manola J, Babcic V, Harnam N, Kantoff P . Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology. 2006; 67(6):1235-40. DOI: 10.1016/j.urology.2006.01.006. View

20.

Chi K, Hotte S, Yu E, Tu D, Eigl B, Tannock I . Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010; 28(27):4247-54. DOI: 10.1200/JCO.2009.26.8771. View